Value of bone resorption markers to predict skeletal related events and response to bisphosphonate therapy in patients with bone metastases : A prspective randomized study /
Nermine Shawki Kamal
Value of bone resorption markers to predict skeletal related events and response to bisphosphonate therapy in patients with bone metastases : A prspective randomized study / قيمة دلالات اورام تأكل العظام لمعرفة تأثيرها على العظام ومدى استجابتها البيسفوسفونات على علاج مرضى الاورام السرطانية المنتشرة بالعظم Nermine Shawki Kamal ; Supervised Wafaa Elmetenawy , Hamdy Abdelazim , Emad Hamada - Cairo : Nermine Shawki Kamal , 2009 - 215P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Oncology (Clinical)
The prospective analysis of urinary N - telopeptides collagen break down products type I (NTX) in patients with metastatic bone disease revealed a positive relation between NTX level and risk of Sketal related events (SREs). Normalization of NTX level at 3 months decreases the rate of serious types of SREs (pathological fractures and cord compression) . Zoledronic acid decreases the rate of one or more SREs by four times in patients with elevated NTX levels compared to no Zoledronic acid
Bone markers Metastatic bone disease N - telopeptides
Value of bone resorption markers to predict skeletal related events and response to bisphosphonate therapy in patients with bone metastases : A prspective randomized study / قيمة دلالات اورام تأكل العظام لمعرفة تأثيرها على العظام ومدى استجابتها البيسفوسفونات على علاج مرضى الاورام السرطانية المنتشرة بالعظم Nermine Shawki Kamal ; Supervised Wafaa Elmetenawy , Hamdy Abdelazim , Emad Hamada - Cairo : Nermine Shawki Kamal , 2009 - 215P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Oncology (Clinical)
The prospective analysis of urinary N - telopeptides collagen break down products type I (NTX) in patients with metastatic bone disease revealed a positive relation between NTX level and risk of Sketal related events (SREs). Normalization of NTX level at 3 months decreases the rate of serious types of SREs (pathological fractures and cord compression) . Zoledronic acid decreases the rate of one or more SREs by four times in patients with elevated NTX levels compared to no Zoledronic acid
Bone markers Metastatic bone disease N - telopeptides